The Swedish health and wellness group Zinzino AB has reported a standout performance for its 2025 fiscal year, delivering results that contrast sharply with the stagnant demand challenging many consumer goods firms. The company’s latest figures reveal not just robust top-line expansion but a dramatic improvement in bottom-line profitability, capturing significant investor attention.
Earnings Momentum and Market Reaction
A key highlight from the annual report is the substantial leap in net profit. Zinzino’s earnings nearly doubled, climbing from SEK 169.17 million in 2024 to SEK 324.32 million in 2025. This powerful increase underscores the company’s effective cost management and its ability to leverage economies of scale, even amid aggressive growth initiatives.
The market has responded positively to this fundamental strength. On a weekly basis, the share price advanced by almost 19 percent, with the stock currently trading at €14.50.
This profit surge was supported by exceptional revenue growth. Total sales for the year expanded by a remarkable 51 percent, reaching SEK 3.34 billion.
Should investors sell immediately? Or is it worth buying Zinzino ABries B?
Regional Drivers and Ongoing Growth
The company’s positive trajectory appears well-established, continuing into the new fiscal year. Preliminary data for January 2026 already indicates a 20 percent year-over-year revenue increase to SEK 281.2 million.
Growth is being fueled primarily by robust demand across North and South American markets. Furthermore, Zinzino is benefiting from increased external sales generated by its manufacturing unit, Faun Pharma. This dual progress demonstrates the company’s successful expansion in both its direct-selling network and its production capabilities.
Investors will be watching closely for the first-quarter results, expected in May, to see if Zinzino can maintain this high-paced growth in its overseas operations throughout the spring season.
Ad
Zinzino ABries B Stock: Buy or Sell?! New Zinzino ABries B Analysis from February 27 delivers the answer:
The latest Zinzino ABries B figures speak for themselves: Urgent action needed for Zinzino ABries B investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 27.
Zinzino ABries B: Buy or sell? Read more here...
